Biofrontera INC 8-K filings

Biofrontera Inc. announced robust second quarter 2026 financial results, highlighted by a 32.9% increase in net product revenue to $12.0 million and a significant improvement in gross margin to 80%.

Biofrontera Inc. held its Annual Meeting of Stockholders on June 11, 2026, where key director elections, an incentive plan amendment, and auditor ratification were approved.

Biofrontera Inc. announced first quarter 2026 financial results, showcasing a 17% revenue increase to $10.1 million and significant gross margin expansion to 80%, alongside progress in its clinical pipeline.

Biofrontera Inc. announced record fourth quarter and full year 2025 financial results, driven by strong Ameluz sales and a favorable new earnout structure.

Biofrontera announced a favorable U.S. Patent Office decision, finding all challenged claims of Sun Pharma's 11,697,028 patent unpatentable, though other litigation continues.

Biofrontera Inc. announced positive and statistically significant top-line results from its Phase 3 clinical trial for Ameluz PDT in treating actinic keratoses on the extremities, neck, and trunk.

Biofrontera Inc. announced preliminary record fourth-quarter 2025 revenues of $17.0M-$17.5M, marking 35-39% year-over-year growth, driven by Ameluz sales.

Biofrontera Inc. received a Nasdaq notice for non-compliance due to its common stock trading below $1.00 per share for 34 consecutive business days.

Biofrontera Inc. reported Q3 2025 financial results, showing a revenue decline attributed to prior-year advanced purchases, while highlighting strategic asset acquisitions and clinical trial progress.

Biofrontera Inc. announced it has regained compliance with Nasdaq's minimum bid price and stockholders' equity listing requirements.

Biofrontera Inc. announced the sale of its U.S. license for Xepi (ozenoxacin) Cream, 1% to Pelthos Therapeutics Inc. for a maximum of $10 million, strengthening its balance sheet and allowing a focus on its photodynamic therapy platform.

Biofrontera Inc. has completed its strategic acquisition of U.S. rights to Ameluz and RhodoLED from Biofrontera AG, supported by an $11 million private placement and a new earnout agreement.

Biofrontera Inc. has closed a restructuring and asset purchase agreement with Biofrontera AG, acquiring full U.S. rights to Ameluz and RhodoLED, backed by an $11 million investment.

Biofrontera Inc. stockholders approved a reverse stock split, conversion of Series C and D Preferred Stock, and related voting changes at a Special Meeting on September 16, 2025.

Biofrontera Inc. reported increased revenues for Q2 2025 and the first half of 2025, alongside a major restructuring of its relationship with Biofrontera AG and progress in clinical trials.

Biofrontera Inc. announced the appointment of George Jones as Chief Commercial Officer, effective August 25, 2025, a strategic move following a significant reduction in Ameluz royalty payments.

Biofrontera Inc. has entered into a strategic agreement to acquire all U.S. rights to Ameluz and RhodoLED from its former parent, Biofrontera AG, in exchange for royalties, preferred stock, and assumption of significant U.S. market costs and legal liabilities.

Biofrontera Inc. has acquired full U.S. rights to its key products Ameluz and RhodoLED from its former parent, funded in part by an $11 million private placement of Series C Convertible Preferred Stock.

Biofrontera Inc. announced a significant restructuring of its relationship with Biofrontera AG, acquiring all U.S. rights to its key products Ameluz and RhodoLED, backed by an $11 million investment aimed at achieving profitability.

Biofrontera Inc. announced that its stockholders approved all proposals at the Annual Meeting, including the election of a Class I director, the ratification of its independent auditor, and a significant increase in authorized common stock.

Biofrontera Inc. announced it is in active negotiations with Biofrontera AG regarding a potential company combination or a significant adjustment to their existing license and supply agreement.

Biofrontera Inc. has filed a supplement to its 2025 Proxy Statement, clarifying that two additional proposals for its upcoming annual meeting are now considered 'routine matters' by the NYSE, impacting how uninstructed broker votes are handled.

Biofrontera Inc. received a notice from Nasdaq indicating non-compliance with continued listing requirements due to insufficient stockholders' equity and failure to meet alternative financial metrics.

Biofrontera Inc. announced an 8.7% increase in total revenues for Q1 2025, driven by Ameluz sales and the launch of the RhodoLED XL Lamp, alongside progress in clinical trials.

Biofrontera Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Biofrontera Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs, effective April 17, 2025, following CBIZ CPAs' acquisition of Marcum's attest business.

Biofrontera Inc. reports record total revenues of $37.3 million for fiscal year 2024, a 9.5% increase from the previous year.

Biofrontera Inc. has finalized a $4.2 million private placement of senior secured convertible notes, set to mature in 2027, with a 10% interest rate.

Biofrontera Inc. has successfully completed a $4.2 million private placement of a senior secured convertible note with its majority shareholders to support general operations and strategic investments.

Biofrontera Inc. reported a 1.5% revenue increase for Q3 2024, which would have been 19% without shipment delays caused by Hurricane Milton, and a 5.6% increase for the first nine months, which would have been 12% without the hurricane impact.